Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2010

Open Access 01-12-2010 | Research

Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom

Authors: Oliver Rivero-Arias, Alastair Gray, Jane Wolstenholme

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2010

Login to get access

Abstract

Background

To estimate life years and quality-adjusted life years (QALYs) lost and the economic burden of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom including healthcare and non-healthcare costs from a societal perspective.

Methods

All UK residents in 2005 with aSAH (International Classification of Diseases 10th revision (ICD-10) code I60). Sex and age-specific abridged life tables were generated for a general population and aSAH cohorts. QALYs in each cohort were calculated adjusting the life tables with health-related quality of life (HRQL) data. Healthcare costs included hospital expenditure, cerebrovascular rehabilitation, primary care and community health and social services. Non-healthcare costs included informal care and productivity losses arising from morbidity and premature death.

Results

A total of 80,356 life years and 74,807 quality-adjusted life years were estimated to be lost due to aSAH in the UK in 2005. aSAH costs the National Health Service (NHS) £168.2 million annually with hospital inpatient admissions accounting for 59%, community health and social services for 18%, aSAH-related operations for 15% and cerebrovascular rehabilitation for 6% of the total NHS estimated costs. The average per patient cost for the NHS was estimated to be £23,294. The total economic burden (including informal care and using the human capital method to estimate production losses) of a SAH in the United Kingdom was estimated to be £510 million annually.

Conclusion

The economic and disease burden of aSAH in the United Kingdom is reported in this study. Decision-makers can use these results to complement other information when informing prevention policies in this field and to relate health care expenditures to disease categories.
Appendix
Available only for authorised users
Literature
1.
van Gijn J, Kerr RS, Rinkel GJ: Subarachnoid haemorrhage. Lancet 2007, 369: 306–318. 10.1016/S0140-6736(07)60153-6PubMedCrossRef
2.
Suarez JI, Tarr RW, Selman WR: Aneurysmal subarachnoid hemorrhage. New England Journal of Medicine 2006, 354: 387–396. 10.1056/NEJMra052732PubMedCrossRef
3.
Wilby MJ, Sharp M, Whitfield PC, Hutchinson PJ, Menon DK, Kirkpatrick PJ: Cost-effective outcome for treating poor-grade subarachnoid hemorrhage. Stroke 2003, 34: 2508–2511. 10.1161/01.STR.0000089922.94684.13PubMedCrossRef
4.
Roos YBWE, Dijkgraaf MGW, Albrecht KW, Beenen LFM, Groen RJM, de Haan RJ, Vermeulen M: Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis. Stroke 2002, 33: 1595–1599. 10.1161/01.STR.0000016401.49688.2FPubMedCrossRef
5.
Wolstenholme J, Rivero-Arias O, Gray A, Molyneux AJ, Kerr RS, Yarnold JA, Sneade M, International Subarachnoid Aneurysm Trial (ISAT): Collaborative Group Treatment pathways, resource use, and costs of endovascular coiling versus surgical clipping after aSAH. Stroke 2008, 39: 111–119. 10.1161/STROKEAHA.107.482570PubMedCrossRef
6.
Lopez AD, et al (Eds): Global Burden of Disease and Risk Factors New York: OUP and WHO; 2006.
7.
Murray CJL, Lopez AD (Eds): Global Comparative Assessments in the Health Sector Geneva: World Health Organization; 1994.
8.
Clabaugh G, Ward MM: Cost-of-illness studies in the United States: A systematic review of methodologies used for direct cost. Value in Health 2008, 11: 13–21.PubMedCrossRef
9.
Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M: Cost of cardiovascular diseases in the United Kingdom. Heart 2006, 92: 1384–1389. 10.1136/hrt.2005.072173PubMedCentralPubMedCrossRef
10.
Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z, Oxford VS: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005, 366: 1773–1783. 10.1016/S0140-6736(05)67702-1PubMedCrossRef
11.
12.
13.
Department of Health: Hospital Episodes Statistics, England: Financial Year 2005–06. London: Department of Health; 2006.
14.
Department of Health: Burden of Disease: A Discussion Document. London: NHS Executive; 1996.
15.
McCormick A, Fleming D, Charlton J: Morbidity statistics from general practice: fourth national study 1991–92. London: HMSO; 1995.
16.
Babb P, et al (Eds): Social Trends no 36 London: Office for National Statistics; 2006.
17.
Molyneux AJ, Kerr RSC, Yu LM, Clarke M, Sneade M, Yarnold JA, Sandercock P: International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005, 366: 809–817. 10.1016/S0140-6736(05)67214-5PubMedCrossRef
18.
Office for National Statistics: Mortality Statistics. London: Office for National Statistics; 2005.
19.
Muennig PA, Gold MR: Using the years-of-healthy-life measure to calculate QALYs. American Journal of Preventive Medicine 2001, 20: 35–39. 10.1016/S0749-3797(00)00261-0PubMedCrossRef
20.
EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9
21.
Kind P, Hardman G, Macran S: UK population norms for EQ-5D. Discussion paper 172: Centre for Health Economics, University of York, UK 1999.
22.
23.
Curtis L, Netten A: Unit costs of health and social care. University of Kent at Canterbury: Personal Social Services Research Unit; 2006.
24.
Clinical Effectiveness Unit: National Study of Subarachnoid Haemorrhage. London: The Royal College of Surgeons of England and the London School of Hygiene and Tropical Medicine; 2006.
25.
Comas-Herrera A, Wittenberg R, Costa-Font J, Gori C, Di Maio A, Patxot C, Pickard L, Pozzi A, Rothgang H: Future long-term care expenditure in Germany, Spain, Italy and the United Kingdom. Ageing & Society 2006, 26: 285–302.CrossRef
26.
Rowlands O: General household survey 1995, supplement A: informal carers. London: The Stationary Office; 1998.
27.
Green H: General household survey 1985, supplement A: informal carers. London: HMSO; 1988.
28.
29.
Office of National Statistics: Annual Survey of Hours and Earnings. London: Office for National Statistics; 2005.
30.
31.
Pritchard C, Sculpher M: Productivity costs: Principles and practice in economic evaluation. London: Office of Health Economics; 2000.
32.
Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992, 34: 1005–1010. 10.1016/0277-9536(92)90131-9PubMedCrossRef
33.
Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M: Economic burden of cardiovascular diseases in the enlarged European Union. European Heart Journal 2006, 27: 1610–1619. 10.1093/eurheartj/ehi733PubMedCrossRef
34.
Katati MJ, Santiago-Ramajo S, Perez-Garcia M, Meersmans-Sanchez JM, Vilar-Lopez R, Coin-Mejias MA, Caracuel-Romero A, rjona-Moron V: Description of quality of life and its predictors in patients with aneurysmal subarachnoid hemorrhage. Cerebrovascular Diseases 2007, 24: 66–73. 10.1159/000103118PubMedCrossRef
35.
Ware JEJ: SF-36 health survey update. Spine 2000, 25: 3130–3139. 10.1097/00007632-200012150-00008PubMedCrossRef
36.
37.
Akobundu E, Ju J, Blatt L, Mullins CD: Cost-of-illness studies: A review of current methods. PharmacoEconomics 2006, 24: 869–890. 10.2165/00019053-200624090-00005PubMedCrossRef
Metadata
Title
Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom
Authors
Oliver Rivero-Arias
Alastair Gray
Jane Wolstenholme
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2010
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-8-6

Other articles of this Issue 1/2010

Cost Effectiveness and Resource Allocation 1/2010 Go to the issue

Research

Cost-effectiveness implications of GP intervention to promote physical activity: evidence from Perth, Australia

Research

Cost recovery of NGO primary health care facilities: a case study in Bangladesh

Research

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

Research

The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study

Review

Can choices between alternative hip prostheses be evidence based? a review of the economic evaluation literature

Research

Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach